Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

GlobeNewsWire

06 Aug 2026, 00:34 UTC · 1h ago

Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit – Hagens Berman

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit – Hagens Berman

What the story claims

3 claims · each scored for market impact

What matters in this story

1
Regeneron's Phase 3 clinical trial of Fianlimab in combination with Libtayo for melanoma failed to reach statistical significance for its primary endpoint of progression-free survival. — The failure of a 'potential blockbuster' therapy removes a significant expected revenue stream and previously wiped $11 billion off the company's market cap.
-0.80
2
A securities class action lawsuit has been filed against Regeneron alleging the company made false and misleading statements regarding the Phase 3 trial's progress and validity. — Litigation introduces legal risk, potential settlement costs, and suggests a lack of transparency in management's communication.
-0.40
3
Regeneron delayed informing investors that it altered the trial protocol in late 2025 to address slow event rates, only revealing the change in April 2026. — Delayed disclosure of protocol changes often signals to the market that a trial is struggling, damaging investor trust in management.
-0.30

6 related stories

GlobeNewsWire
4h ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of ARS Pharmaceuticals, Inc. Securities and Sets a Lead Plaintiff Deadline of October 5, 2026
- class action
- lawsuit
- pharmaceuticals
Read

Regeneron Pharmaceuticals… — REGN -1.00 | NewsImpactScreener

Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit – Hagens Berman

What matters in this story

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of ARS Pharmaceuticals, Inc. Securities and Sets a Lead Plaintiff Deadline of October 5, 2026

Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit – Hagens Berman

What matters in this story

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of ARS Pharmaceuticals, Inc. Securities and Sets a Lead Plaintiff Deadline of October 5, 2026

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Kaplan Fox Alerts Investors of Coastal Financial Corporation (CCB) to an Investigation of Potential Securities Law Violations

Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm

BRCB DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Black Rock Coffee Bar, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 17 Deadline in Securities Class Action - BRCB

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM LAW FIRM, Encourages Planet Fitness, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PLNT

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR

Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit – Hagens Berman

What matters in this story

Next reads from the same story arc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of ARS Pharmaceuticals, Inc. Securities and Sets a Lead Plaintiff Deadline of October 5, 2026

Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit – Hagens Berman

What matters in this story

Next reads from the same story arc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of ARS Pharmaceuticals, Inc. Securities and Sets a Lead Plaintiff Deadline of October 5, 2026

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Kaplan Fox Alerts Investors of Coastal Financial Corporation (CCB) to an Investigation of Potential Securities Law Violations

Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm

BRCB DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Black Rock Coffee Bar, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 17 Deadline in Securities Class Action - BRCB

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM LAW FIRM, Encourages Planet Fitness, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PLNT

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR